mRNA expression of DOK1-6 in human breast cancer

Table 4 Downstream of tyrosine kinases (4-6) mRNA expression levels (mean ± SD)

Patient and tumour characteristics	DOK-4	P	DOK-5	P	DOK-6	P
NPI
1 vs 2	415 ± 1444 vs 94.7 ± 275	0.170	31504 ± 163256 vs 2466 ± 7194	0.23	15.4 ± 39.98 vs 7.55 ± 18.37	0.270
1 vs 3	415 ± 1444 vs 103.4 ± 182.6	0.180	31504 ± 163256 vs 88648 ± 287508	0.52	15.4 ± 39.98 vs 0.218 ± 0.468	0.018
2 vs 3	94.7 ± 275 vs 103.4 ± 182.6	0.910	2466 ± 7194 vs 88648 ± 287508	0.32	7.55 ± 18.37 vs 0.218 ± 0.468	0.048
Tumour grade
1 vs 2	589 ± 1860 vs 188 ± 819	0.410	68655 ± 261421 vs 5756 ± 14725	0.32	12.96 ± 28.62 vs 12.41 ± 39.55	0.960
1 vs 3	589 ± 1860 vs 147.5 ± 623.8	0.350	68655 ± 261421 vs 28639 ± 155311	0.55	12.96 ± 28.62 vs 6.22 ± 21.56	0.430
2 vs 3	188 ± 819 vs 147.5 ± 623.8	0.830	5756 ± 14725 vs 28639 ± 155311	0.35	12.41 ± 39.55 vs 6.22 ± 21.56	0.440
TNM
1 vs 2	229 ± 829 vs 403 ± 1568	0.610	27103 ± 152075 vs 5096 ± 19916	0.30	10.26 ± 33.54 vs 13.68 ± 32.53	0.680
1 vs 3	229 ± 829 vs 83.9 ± 222	0.330	27103 ± 152075 vs 200882 ± 446722	0.44	10.26 ± 33.54 vs 2.07 ± 4.62	0.130
1 vs 4	229 ± 829 vs 49.4 ± 62.1	0.160	27103 ± 152075 vs 0.198 ± 0.184	0.20	10.26 ± 33.54 vs 0.0734 ± 0.1464	0.048
2 vs 3	403 ± 1568 vs 83.9 ± 222	0.340	5096 ± 19916 vs 200882 ± 446722	0.38	13.68 ± 32.53 vs 2.07 ± 4.62	0.098
2 vs 4	403 ± 1568 vs 49.4 ± 62.1	0.280	5096 ± 19916 vs 0.198 ± 0.184	0.11	13.68 ± 32.53 vs 0.0734 ± 0.1464	0.047
3 vs 4	83.9 ± 222 vs 49.4 ± 62.1	0.720	200882 ± 446722 vs 0.198 ± 0.184	0.37	2.07 ± 4.62 vs 0.0734 ± 0.1464	0.340
Survival
DF vs LR	328 ± 1205 vs 2.22 ± 2.5	0.038	23013 ± 139049 vs 10477 ± 22630	0.53	11.38 ± 33.96 vs 9.24 ± 18.47	0.840
DF vs DR	328 ± 1205 vs 40.5 ± 77.9	0.074	23013 ± 139049 vs 1022 ± 2240	0.21	11.38 ± 33.96 vs 20.7 ± 35.8	0.700
DF vs DR	328 ± 1205 vs 84.1 ± 185	0.140	23013 ± 139049 vs 81855 ± 276356	0.47	11.38 ± 33.96 vs 0.209 ± 0.45	0.013

DOK: Downstream of tyrosine kinase; NPI: Nottingham Prognostic Index; DF: Disease Free; LR: Local Recurrence; DR: Distant Recurrence.